Sequential treatment with AT-101 enhances cisplatin chemosensitivity in human non-small cell lung cancer cells through inhibition of apurinic/apyrimidinic endonuclease 1-activated IL-6/STAT3 signaling pathway

AT-101, known as R-(–)-gossypol, is a potent anticancer agent, but its chemosensitizing effects remain elusive. The present study aimed to examine whether AT-101 could increase the sensitivity of non-small cell lung cancer A549 cells to cisplatin (CDDP) and the underlying mechanisms. We evaluated th...

Descripción completa

Detalles Bibliográficos
Autores principales: Ren, Tao, Shan, Jinlu, Qing, Yi, Qian, Chengyuan, Li, Qing, Lu, Guoshou, Li, Mengxia, Li, Chongyi, Peng, Yu, Luo, Hao, Zhang, Shiheng, Zhang, Weiwei, Wang, Dong, Zhou, Shu-Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4271790/
https://www.ncbi.nlm.nih.gov/pubmed/25548514
http://dx.doi.org/10.2147/DDDT.S71432

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4271790/
https://www.ncbi.nlm.nih.gov/pubmed/25548514
http://dx.doi.org/10.2147/DDDT.S71432

Ejemplares similares